243 related articles for article (PubMed ID: 31960110)
1. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
[TBL] [Abstract][Full Text] [Related]
2. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA
Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299
[TBL] [Abstract][Full Text] [Related]
3. microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.
Mari L; Hoefnagel SJM; Zito D; van de Meent M; van Endert P; Calpe S; Sancho Serra MDC; Heemskerk MHM; van Laarhoven HWM; Hulshof MCCM; Gisbertz SS; Medema JP; van Berge Henegouwen MI; Meijer SL; Bergman JJGHM; Milano F; Krishnadath KK
Gastroenterology; 2018 Sep; 155(3):784-798. PubMed ID: 29885883
[TBL] [Abstract][Full Text] [Related]
4. Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma.
McLaren PJ; Barnes AP; Terrell WZ; Vaccaro GM; Wiedrick J; Hunter JG; Dolan JP
Am J Surg; 2017 May; 213(5):915-920. PubMed ID: 28385379
[TBL] [Abstract][Full Text] [Related]
5. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition.
Donlon NE; Davern M; Sheppard AD; O'Connell F; Dunne MR; Hayes C; Mylod E; Ramjit S; Temperley H; Mac Lean M; Cotter G; Bhardwaj A; Butler C; Conroy MJ; O'Sullivan J; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Front Immunol; 2022; 13():823225. PubMed ID: 35154142
[TBL] [Abstract][Full Text] [Related]
7. TGM2: a cell surface marker in esophageal adenocarcinomas.
Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.
Abdel-Latif MM; O'Riordan J; Windle HJ; Carton E; Ravi N; Kelleher D; Reynolds JV
Ann Surg; 2004 Apr; 239(4):491-500. PubMed ID: 15024310
[TBL] [Abstract][Full Text] [Related]
9. Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma.
Galvin KC; Conroy MJ; Doyle SL; Dunne MR; Fahey R; Foley E; O'Sullivan KE; Doherty DG; Geoghegan JG; Ravi N; O'Farrelly C; Reynolds JV; Lysaght J
Cancer Lett; 2018 Apr; 418():230-238. PubMed ID: 29339209
[TBL] [Abstract][Full Text] [Related]
10. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
Langer R; Specht K; Becker K; Ewald P; Bekesch M; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
Clin Cancer Res; 2005 Oct; 11(20):7462-9. PubMed ID: 16243820
[TBL] [Abstract][Full Text] [Related]
11. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus.
Schoemmel M; Loeser H; Kraemer M; Wagener-Ryczek S; Hillmer A; Bruns C; Thelen M; Schröder W; Zander T; Lechner A; Buettner R; Schlösser H; Gebauer F; Quaas A;
Clin Transl Oncol; 2021 Aug; 23(8):1601-1610. PubMed ID: 33566304
[TBL] [Abstract][Full Text] [Related]
12. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
[TBL] [Abstract][Full Text] [Related]
13. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
14. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.
Tanaka K; Otake K; Mohri Y; Ohi M; Yokoe T; Toiyama Y; Miki C; Tonouchi H; Kusunoki M
Oncol Rep; 2009 Jun; 21(6):1489-94. PubMed ID: 19424628
[TBL] [Abstract][Full Text] [Related]
16. Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.
Lynam-Lennon N; Bibby BA; Mongan AM; Marignol L; Paxton CN; Geiersbach K; Bronner MP; O'Sullivan J; Reynolds J; Maher SG
Mol Med; 2016 May; 22():388-97. PubMed ID: 27254108
[TBL] [Abstract][Full Text] [Related]
17. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
[TBL] [Abstract][Full Text] [Related]
18. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.
Odenthal M; Hee J; Gockel I; Sisic L; Schmitz J; Stoecklein NH; Driemel C; Möhlendick B; Schmidt T; Knoefel WT; Lang H; Büttner R; Ott K; Vallböhmer D
Int J Cancer; 2015 Jul; 137(1):230-7. PubMed ID: 25429911
[TBL] [Abstract][Full Text] [Related]
19. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing.
Chiam K; Mayne GC; Watson DI; Woodman RJ; Bright TF; Michael MZ; Karapetis CS; Irvine T; Phillips WA; Hummel R; Wang T; Pimlott LK; Marri S; Astill DS; Ruszkiewicz AR; Thompson SK; Hussey DJ
Ann Surg Oncol; 2018 Sep; 25(9):2731-2738. PubMed ID: 29987600
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
